There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Life's End Benefits of Cannabidiol and Tetrahydrocannabinol
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
05/16/2024
Locations: Ralph H. Johnson VA Medical Center, Charleston, South Carolina
Conditions: Agitation, Dementia
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Recruiting
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
05/16/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Sickle Cell Disease
Implementation and Effectiveness Trial of HN-STAR
Recruiting
People who have been treated for head and neck cancer (HNC survivors) can experience serious consequences from their cancer and its treatment, ongoing risks of new cancers, and other unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors. Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health concerns before a routine visit with... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Head and Neck Cancer
Beat Childhood Cancer Specimen Banking and Data Registry
Recruiting
This is an observational data registry study of all pediatric cancer patients at Atrium Health (AH) and participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Gender:
All
Ages:
All
Trial Updated:
05/16/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pediatric Cancer
Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)
Recruiting
This is a Phase III clinical trial to compare the efficacy of two dosages of a new infant rehabilitation protocol - I-ACQUIRE - to usual and customary forms of infant rehabilitation in infants who experienced Perinatal Arterial Stroke (PAS).
Gender:
All
Ages:
Between 8 months and 36 months
Trial Updated:
05/15/2024
Locations: The Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Perinatal Stroke, Hemiparesis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/15/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Plaque Psoriasis
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
All
Ages:
12 years and above
Trial Updated:
05/15/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Primary Generalized Tonic-Clonic Seizures
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Recruiting
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.
Gender:
All
Ages:
16 years and above
Trial Updated:
05/15/2024
Locations: Clinical Research Center of the Carolinas, Charleston, South Carolina
Conditions: Acne Vulgaris
Young Adult Tobacco/Nicotine and Cannabis Co-use
Recruiting
The goal of this project is to better understand the relationship between tobacco/nicotine and cannabis using behavioral economics during a tobacco/nicotine quit attempt. All participants will receive tobacco/nicotine cessation treatment (smoking and/or vaping treatment) for 12 weeks. To qualify, participants must be between the ages of 18-25 and use tobacco products (smoke cigarettes and/or vape nicotine) and use cannabis (in any form). Participants do not need to be interested in quitting cann... Read More
Gender:
All
Ages:
Between 18 years and 25 years
Trial Updated:
05/15/2024
Locations: Medical University of South Carolina - Charleston, Charleston, South Carolina
Conditions: Tobacco Use Disorder, Nicotine Dependence
An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Recruiting
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Zai Lab Site 2012, Charleston, South Carolina
Conditions: SCLC
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Clinical Research Center of the Carolinas, LLC, Charleston, South Carolina
Conditions: Plaque Psoriasis